-- Kendle is proud to have worked with 46 of the top 50 global
biopharmaceutical companies to speed their drugs to market.
-- Kendle is one of only two global CROs to have at least 50 percent of
its revenues outside of the United States, according to industry
analyst Jefferies & Company, Inc.
-- Kendle's net service revenues have increased from $44 million for
Fiscal Year 1997 when the company first started trading on NASDAQ to
$283.5 million at the end of 2006.
-- Kendle increased its size by 50 percent from 2006 to 2007 through the
acquisition of the Phase II-IV business of Charles River Clinical
Services, Inc., adding attractive therapeutic expertise, diversifying
its customer base and expanding its capacity to deliver global trials.
-- Kendle's customer-focused approach to delivery of Phase I-IV clinical
development services has resulted in sales growth above the industry
average for three consecutive years, with sales for 2006 at triple the
reported average sector growth rate.
-- Proprietary company quantitative research conducted in 2006 showed
Kendle's reputation as a first-choice partner for Phase III studies
grew significantly with the company perceived as a top three global CRO
in this area, one of the areas of greatest market opportunity in the
-- Kendle has been recognized as the "Top CRO to Work With" in the Thomson
CenterWatch 2007 Survey of U.S. Investigative Sites and as the "Best
Contract Research Organization" in November 2006 by an independent
panel for Scrip World Pharmaceutical News.
-- As one of the early CROs Kendle is actively shaping the future of our
industry as one of the five founding and active members of the
Association of Clinical Research Organizations (ACRO) established in'/>"/>
|SOURCE Kendle International Inc.|
Copyright©2007 PR Newswire.
All rights reserved